Radiosensitizers in hepatocellular carcinoma

Area of Science:

• Oncology
• Radiation Oncology
• Hepatocellular Carcinoma Research

Background:

• Hepatocellular carcinoma (HCC) often presents as locally advanced disease with metastatic potential.
• Conformal radiotherapy (RT) offers local control for focal HCC but is limited in advanced cases by toxicity risks.
• Radiation-induced liver toxicity and gastrointestinal organ toxicity restrict achievable RT doses in locally advanced HCC.

Purpose of the Study:

• To review the rationale for using radiation sensitizers in combination with RT for HCC.
• To discuss the existing clinical experience of combining RT with various radiosensitizing agents in HCC treatment.

Main Methods:

• Literature review of studies combining radiotherapy with radiosensitizers for hepatocellular carcinoma.
• Analysis of clinical data on the efficacy and toxicity of combined RT and radiosensitizer approaches.
• Exploration of different classes of radiosensitizers, including chemotherapy and molecular targeted agents.

Main Results:

• Clinical experience combining RT with radiosensitizers in HCC is currently limited.
• Hepatic arterial chemoembolization (TACE) and halogenated pyrimidines have been explored with RT.
• Emerging data shows increasing use of RT with molecular targeted agents in HCC.

Conclusions:

• Combining RT with radiosensitizers is a promising strategy to enhance the therapeutic ratio in HCC.
• Further clinical investigation is needed to establish optimal radiosensitizing agents and protocols for HCC.
• The development of novel radiosensitizers holds potential for improving outcomes in advanced HCC.